Every 10-Q that Cumberland Pharmaceuticals Inc (CPIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CPIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPIX filings page.
Cumberland Pharmaceuticals Inc. executed a major strategic shift, completing on July 1, 2026 the sale of its FDA‑approved branded products to Apotex for $100 million in cash, plus up to $9 million of inventory reimbursement and approximately $2 million for transition services. The company will now operate as a development‑stage biopharmaceutical business focused on its ifetroban clinical programs and early‑stage candidates at Cumberland Emerging Technologies.
For the six months ended June 30, 2026, net revenues from continuing operations were $330,308 and the net loss from continuing operations was $5,962,447. Including discontinued operations, net loss attributable to common shareholders was $7,566,016, compared with net income of $516,328 in the prior‑year period, reflecting weaker results from the divested brand portfolio.
Cash and cash equivalents were $3,862,402 at June 30, 2026, before receipt of Apotex proceeds and repayment of the $5.2 million revolving credit facility. Management states that cash on hand, the $100 million transaction proceeds and inventory reimbursement will fund operations for at least twelve months. The board declared a special cash dividend of $1.50 per share, totaling $22.5 million, and authorized a new $5 million share repurchase program.
Cumberland Pharmaceuticals reported a weak quarter while outlining a transformative strategic deal. For the three months ended March 31, 2026, net revenues were $9.1 million and the company posted a net loss of $3.3 million, compared with net income of $1.2 million a year earlier. Operating cash flow remained positive at $0.4 million, but working capital turned slightly negative, with current liabilities exceeding current assets by about $1.7 million.
Subsequent to quarter-end, Cumberland agreed to sell the assets and U.S. rights to its portfolio of FDA‑approved brands to an affiliate of Apotex Inc. for $100 million in cash, subject to shareholder approval and closing conditions. The company will retain its ifetroban development programs and Cumberland Emerging Technologies, transitioning toward a development‑stage profile. The agreement also provides for a potential Vibativ milestone payment, up to $9 million of inventory reimbursement one year after closing, and monthly transition‑services fees of $150,000 plus certain reimbursed costs.
Cumberland Pharmaceuticals (CPIX) filed its Q3 2025 report, showing quarterly net revenue of $8.29M versus $9.09M a year ago and a net loss of $1.95M. For the first nine months, revenue rose to $30.84M from $27.43M as growth in Sancuso and Vibativ offset weaker Kristalose.
Sancuso delivered $3.24M in Q3 sales (up year over year) and Vibativ $2.60M, while Kristalose fell to $1.18M amid authorized‑generic shipment delays and higher generic substitution. Cost of products sold was $0.99M, supporting strong gross margin.
Operating cash flow turned positive at $4.93M year‑to‑date, aided by working capital, while cash ended at $15.20M. Debt on the revolving credit facility declined to $5.24M. The company issued 1,000,000 shares via ATM for proceeds of about $5.5M. Shares outstanding were 14,956,627 as of November 5, 2025.
After quarter end, Cumberland and RedHill formed a joint company to co‑commercialize Talicia in the U.S., with Cumberland committing $4M over two years and recording U.S. product sales under an equal net‑revenue share.
Cumberland Pharmaceuticals reported six-month net revenues of $22.55 million, up from $18.35 million a year earlier, driven mainly by higher sales of Sancuso, Vibativ, Caldolor and Acetadote, while Kristalose sales declined. For the six months ended June 30, 2025 the company recorded a $512,977 net income versus a $3.01 million loss a year earlier, reflecting improved operating results and a $3.0 million milestone recognized related to Vibativ.
Cash and liquidity show $16.09 million in cash, positive operating cash flow of $4.74 million for the six months, and working capital of $7.23 million. Borrowings under the revolving credit facility were $5.24 million at June 30, 2025 (down from $15.3 million at year-end). Clinical and commercial developments include Phase II ifetroban results (a reported 5.4% cardiac improvement in DMD), an upcoming FDA meeting, new Vibativ supply/pack configurations and a published pharmacokinetic analysis supporting dosing.